Spl-memantine-chemical-structure (Spl Memantine Chemical Structure)
Memantine Hydrochloride
Product Images NDC 67046-458
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 67046-458). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Contract Pharmacy Services-pa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Spl-memantine-figure1 (Spl Memantine Figure1)
This is a graph showing the time course of clinical improvement and decline in patients completing 28 weeks of treatment with Placebo and Memantine Hydrochloride. The change from baseline in ADCS-ADL score is plotted on the y-axis against the number of weeks of treatment on the x-axis.*
Spl-memantine-figure2 (Spl Memantine Figure2)
The figure labeled "Figure 2" shows the cumulative percentage of patients who completed 28 weeks of double-blind treatment with specified changes from baseline in ADCS-ADL scores. The text includes the names of two drugs - Placebo and Memantine Hydrochloride.*
Spl-memantine-figure3 (Spl Memantine Figure3)
This is a graph displaying the time course of change from baseline in SIB Score for patients who completed 28 weeks of treatment. The graph shows the mean change from baseline for placebo and memantine hydrochloride groups. The x-axis shows weeks of treatment while the y-axis shows the SIB score.*
Spl-memantine-figure4 (Spl Memantine Figure4)
The text describes a figure labeled "Figure 4", which shows the cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in SIB (Severe Impairment Battery) scores. The figure compares the effectiveness of two treatments, Placebo and Memantine Hydrochloride.*
Spl-memantine-figure5 (Spl Memantine Figure5)
The text is describing a figure showing the time course of change from baseline in ADCS-ADL score for patients completing 24 weeks of treatment with either Placebo/Donepezil or Memantine Hydrochloride/Donepezil. The figure shows that Memantine Hydrochloride/Donepezil resulted in a clinical improvement while Placebo/Donepezil did not. The text also mentions "Mean (+SEM) Change from Baseline" but no specific information is provided.*
Spl-memantine-figure6 (Spl Memantine Figure6)
This is a graph that shows the cumulative percentage of patients who completed 24 weeks of double-blind treatment with the specified changes from baseline in ADCS-ADL scores. The graph compares two treatments: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. There are no other details available to provide.*
Spl-memantine-figure7 (Spl Memantine Figure7)
The text provides a graph displaying the time course of the change from baseline in SIB score for patients completing 24 weeks of treatment. The SIB score is evaluated in the context of Placebo/Donepezil Clinical Dectn and Memantine Hydrochloride/Donepezil treatments. The mean change from baseline is also presented.*
Spl-memantine-figure8 (Spl Memantine Figure8)
The text describes a figure labeled "Figure 8" that shows the percentage of patients completing 24 weeks of double-blind treatment with specified changes from baseline in SIBscores. The figure displays two treatment groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The x-axis shows a range of scores from 20 to -30, and the y-axis shows the cumulative percentage of patients.*
Spl-memantine-label-10mg (Spl Memantine Label 10mg)
Memantine is a prescription medication with 10mg tablets containing memantine hydrochloride, intended for control of symptoms of dementia. It must be kept in storage between 20 to 25°C (66-77°F), with allowable excursions in temperature from 15-30°C (56-86°F). The medication is packaged by Contract Pharmacy Services and contains a lot number and expiration date. Further dosage information is present in the accompanying prescribing documentation. *
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
